ASTM, GERN, CTII, HYSQ, ... remember there is a biotech conference next week. This has the potential to not only highlight these stocks, but to get the media attracted to them, thus creating publicity, thus increasing share price. BTW, HYSQ is a very important player that has been somewhat ignored, recently. They have a huge potential as they are one of the foremost leaders in gene sequencing, functional genomics, and bioinformatics. They also have a lot of new stuff that they have put into the pipeline this year relating to vaccines, etc. This is a company to hold in your pocket, as they are grossly undervalued, at this time, and a look at the chart shows virtually no downside and vast upside. Also, Perkin-Elmer has teamed with Hyseq with Hyseq's "HyChip", the world's only universal gene sequencing microchip. This chip is why Hyseq leads the world in the quantity of the human genome sequence that has been sequenced, to date.
Biotech, in my opinion, is the next "internut". It has been a long time in the making, with a lot of false starts, but the results that have been published by the likes of GERN, CTII, ASTM, HYSQ, etc. are now hinting that the real breakthroughs are just around the corner.
Remember, when Dolly the sheep was cloned, they kept saying that human cloning was y-e-a-r-s away. Well, I'm not a biologist, but it seems to me that a human is not that much more complex than a sheep, from a strictly biological point of view. If you can clone a higher mammal, like a sheep, it seems to me you could clone a human. Now, of course, it turns out that the Koreans have announced that they have, essentially, done that, although they did not implant the embryos, and thus the research did not go any further (or at least so they say.)
These recent discoveries in the area of stem cell research and gene sequencing may well be the MOST significant scientific discoveries of the 20th century. Wouldn't it be wonderful if some of the research becomes more practical in the last year of the century and the millenium!?
Just my 2 cents,
Ed
|
